Cefixime Powder, For Suspension
Product Images NDC 65862-751

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Cefixime (NDC 65862-751). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Label-principal Display Panel (100 mg/5 mL (50 mL Bottle))

Package Label-principal Display Panel (100 mg/5 mL (50 mL Bottle))
Cefixime for Oral Suspension is a prescription medicine in the form of a reconstituted suspension for oral use only, produced by Aurbindo Pharma USA, Inc. The drug powder must be stored at 20° to 25°C (68° to 77°F) prior to reconstitution, and the reconstituted suspension should be stored under refrigeration or at room temperature. One bottle of the suspension is intended for dispensing and should only be used if the seal is intact. The usual dosage is indicated in the package insert and each mL (measured with a spoon) of the reconstituted suspension contains cefixime trihydrate equivalent to 100 mg of cefixime. The net contents of the bottle contains 1 gram of cefixime trihydrate. After 14 days, discard any unused portion of the suspension. The code "TS/DRUGSTE86" and a date of constitution may be printed in the overprinting zone, while a dotted line in the coding area should not be printed.*
FDA Label Image

Package Label-principal Display Panel (200 mg/5 mL (50 mL Bottle))

FDA Label Image

Chemical Structure (Cefixime Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.